Members can submit topics for guideline development or new evidence to support an update of an existing guideline each year by August 1. Member-suggested topics will be provided to the appropriate ...

First awarded in 1992, the CDA provides three years of research funding to clinical investigators in the first to fourth year of faculty appointment to establish an independent clinical cancer ...

"This trial raises an intriguing hypothesis: that the increasingly popular GLP-1 medications used to treat diabetes and obesity might offer some benefit in reducing the risk of developing cancer. I ...

“The INAVO120 trial has identified a targeted treatment regimen that meaningfully improves survival in patients with untreated PIK3CA-mutated hormone receptor-positive metastatic breast cancer – a big ...

“Immunotherapy has improved survival outcomes for patients with extensive-stage small cell lung cancer (ES-SCLC), marking meaningful progress in a historically challenging disease. However, despite ...

“Accurate HER2 scoring is important to ensure that patients receive the best treatment for their breast cancer. This international study shows that an AI-assisted approach improved HER2 scoring, ...

ALEXANDRIA, Va., and SUNNYVALE, Calif.– The American Society of Clinical Oncology (ASCO) and Google Cloud today announced a powerful collaboration to launch an AI-based ASCO Guidelines Assistant.

Conquer Cancer®, the ASCO Foundation and Pfizer External Research & Grants are collaborating to offer a Quality Improvement grant funding opportunity to improve the patient experience in bladder ...

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur: On May 15, 2025, the Food and Drug Administration approved retifanlimab-dlwr (Zynyz, Incyte ...

Who does this study affect? People with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer that has grown after hormone ...

Who does this study affect? Patients with extensive-stage small cell lung cancer (ES-SCLC) that has been previously treated What did this study find? The phase 3 IMforte study found that patients with ...

Disclaimer This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information ...